About this trial
This multicentre pilot trial will assess the feasibility of a full-scale, randomized trial to determine whether bloodwork guided dosing of blood thinners reduces the risk of clotting in high-risk trauma patients. Patients will receive either standard of care dosing or dosing with adjustments based on bloodwork to achieve a minimum therapeutic threshold.
Eligibility criteria
Qualifiers
Patients 18 years of age or older admitted to a hospital ward or intensive care unit following a traumatic injury involving two or more body systems (head, chest, abdomen, pelvis, extremity) and meeting at least one of the following high-risk criteria previously identified in a recent systematic review (1): age ≥ 65, body mass index ≥ 30 kg/m2, injury severity score ≥ 16, pelvic injury with activity restrictions, lower extremity injury with activity restrictions, or surgery during the index hospitalization.
Disqualifiers
Greater than 7 days since time of injury.
Requirement for therapeutic anticoagulation or dual-antiplatelet therapy
Unable or unwilling to receive pharmacologic prophylaxis within 48 hours of admission.
History of allergic reaction or sensitivity to LMWH.
Trial design
Treatments tested in this trial
- Anti-Xa Guided Dosing of Low Molecular Weight Heparin
- Standard of Care Dosing
Treatment groups
Locations
Sponsors and collaborators
Alexandre Tran
Lead sponsor
Ottawa Hospital Research Institute
Sponsor institution